Last reviewed · How we verify
CSL830
At a glance
| Generic name | CSL830 |
|---|---|
| Sponsor | Joshua S. Jacobs, MD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Expanded Access for Hereditary Angioedema (HAE)
- A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL830 CI brief — competitive landscape report
- CSL830 updates RSS · CI watch RSS
- Joshua S. Jacobs, MD portfolio CI